Cost-Utility Analysis of Direct-Acting Antivirals for Treatment of Chronic Hepatitis C Genotype 1 and 6 in Vietnam

OBJECTIVE: Very few cost-utility analyses have either evaluated direct-acting antivirals (DAAs) on hepatitis C virus (HCV) genotype 6 patients or undertaken societal perspective. Recently, DAAs have been introduced into the Vietnamese health insurance drug list for chronic hepatitis C (CHC) treatmen...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Value Health
Auteurs principaux: Due, Ong The, Thakkinstian, Ammarin, Thavorncharoensap, Montarat, Sobhonslidsuk, Abhasnee, Wu, Olivia, Phuong, Nguyen Khanh, Chaikledkaew, Usa
Format: Artigo
Langue:Inglês
Publié: Elsevier 2020
Sujets:
Economic Evaluation
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7491253/
https://ncbi.nlm.nih.gov/pubmed/32940236
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jval.2020.03.018
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires